Increasing prevalence of allergic conditions, including allergic rhinitis, hay fever, and hives is a significant driver of the market.
For instance, according to the National Center for Health Statistics, the prevalence of diagnosed allergic conditions in adults in the U.S. in 2021 was 28.2%, with allergic rhinitis being one of the conditions included in this category. Similarly, a study published in 2023 by the National Institute of Health (NHI), reported that the global prevalence of allergic rhinitis was 20% in 2018, but it is estimated to have been 10 to 15% in 2021.
Loratadine, a second-generation antihistamine, is commonly used to relieve symptoms associated with these allergic reactions. Thus, as allergies become more common globally, driven by factors such as environmental changes, pollution, and genetic predispositions, the demand for effective allergy therapeutics like loratadine continues to rise.
Further, easy availability of loratadine as over the counter (OTC) drug has greatly contributed to its market growth. The OTC availability allows consumers easier access to the medication without the need for a doctor's prescription, leading to increased sales and usage. This accessibility has made loratadine a preferred choice for many individuals seeking relief from allergies, further boosting its market demand and expansion.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The loratadine market was valued at USD 140.1 million in 2023 and is anticipated to grow at 2.8% CAGR between 2024
The tablets segment in the loratadine industry accounted for USD 63.5 million in 2023, due to their convenience, ease of administration, and familiarity.
North America loratadine market is anticipated to reach USD 62 million by 2032, attributed to the high prevalence of allergies in the region and the well-established healthcare infrastructure and high awareness about allergy management.
Bayer AG, Cadila Pharmaceuticals Limited, Cipla Ltd., Lannett Company, Inc., Merck KGaA, Morepen Laboratories Ltd, Perrigo Company plc, Pfizer Inc, Sun Pharmaceutical Industries Limited and Viatris Inc.